-
2024.9.3
Prognostic significance of LAT1 expression in pleural mesothelioma.
著者 Taguchi R, Kaira K, Miura Y, Umesaki T, Mouri A, Imai H, Kagamu H, Yasuda M, Kanai Y, Nitanda H, Ishida H, Sakaguchi H.
Heliyon. 2024 Sep 3;10(17):e37414. doi: 10.1016/j.heliyon.2024.e37414. eCollection 2024 Sep 15.
PMID: 39290273 Free PMC article.
-
2024.9.1
A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.
著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.
Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.
PMID: 39287161 Free PMC article. Review.
-
2024.8.5
The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.
著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.
Oncology. 2024 Aug 5:1-11. doi: 10.1159/000540651. Online ahead of print.
PMID: 39102792
-
2024.7.3
Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation.
著者 Ito K, Kaira K, Imai H, Shiono A, Hashimoto K, Yamaguchi OU, Kagamu H.
Cancer Diagn Progn. 2024 Jul 3;4(4):529-533. doi: 10.21873/cdp.10359. eCollection 2024 Jul-Aug.
PMID: 38962554 Free PMC article.
-
2024.7.1
Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.
著者 Kaira K, Mouri A, Imai H, Yamaguchi O, Kagamu H.
Curr Oncol Rep. 2024 Sep;26(9):1113-1119. doi: 10.1007/s11912-024-01571-0. Epub 2024 Jul 1.
PMID: 38954314 Review.
-
2024.6.1
Progression to Lymph Node Metastasis After Spontaneous Regression of Pulmonary Adenocarcinoma Following Biopsy.
著者 Kaira K, Imai H, Mouri A, Yamaguchi OU, Kagamu H.
In Vivo. 2024 May-Jun;38(3):1498-1502. doi: 10.21873/invivo.13597.
PMID: 38688648 Free PMC article.
-
2024.6.1
Membranous Nephropathy as a Paraneoplastic Syndrome in Cancer of Unknown Primary.
著者 Kaira K, Amano H, Imai H, Okada H, Kagamu H.
In Vivo. 2024 May-Jun;38(3):1503-1508. doi: 10.21873/invivo.13598.
PMID: 38688636 Free PMC article.
-
2024.5.31
Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review.
著者 Kaira K, Ichiki Y, Imai H, Kawasaki T, Hashimoto K, Kuji I, Kagamu H.
Transl Lung Cancer Res. 2024 May 31;13(5):1137-1149. doi: 10.21037/tlcr-24-142. Epub 2024 May 24.
PMID: 38854945 Free PMC article. Review.
-
2024.5.31
Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma.
著者 Kaira K, Imai H, Kagamu H.
Transl Lung Cancer Res. 2024 May 31;13(5):1177-1182. doi: 10.21037/tlcr-24-193. Epub 2024 May 27.
PMID: 38854932 Free PMC article. No abstract available.
-
2024.5.20
Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer.
著者 Hashimoto K, Kaira K, Imai H, Shiono A, Kagamu H.
J Chemother. 2024 May 20:1-3. doi: 10.1080/1120009X.2024.2352985. Online ahead of print.
PMID: 38766697
-
2024.5.20
D-dimer cut-off value for predicting venous thromboembolism at the initial diagnosis in Japanese patients with advanced lung cancer.
著者 Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Masuda T, Kubota T, Kobayashi K, Isobe T.
Jpn J Clin Oncol. 2024 May 20:hyae064. doi: 10.1093/jjco/hyae064. Epub ahead of print.
PMID: 38769814.
-
2024.5.20
Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer.
著者 Hashimoto K, Kaira K, Imai H, Shiono A, Kagamu H.
J Chemother. 2024 May 20:1-3. doi: 10.1080/1120009X.2024.2352985. Online ahead of print.
PMID: 38766697
RESEARCH 研究の報告
